Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence

Pharmaceutics · 2026 Oct 9 · Mateescu DM, Capraru ID, Enache B et

By Maren Holt · Senior Reporter, GLP-1

Oct 8 20:00 ETSource: Pharmaceutics

From the source

Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence
Pharmaceutics · 2026 Oct 9 · Mateescu DM, Capraru ID, Enache B et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42942810/